Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121817 | 0.93 | AR (0.56) | ARNR3C1PGR | |
| SCHEMBL5495691 | 0.93 | AR (0.56) | ARNR3C1PGR | |
| SCHEMBL5489778 | 0.92 | AR (0.56) | ARNR3C1PGR | |
| SCHEMBL5126210 | 0.92 | AR (0.56) | ARNR3C1PGR | |
| SCHEMBL5125424 | 0.90 | AR (0.55) | ARNR3C1PGR | |
| SCHEMBL5129571 | 0.90 | AR (0.58) | ARNR3C1PGR | |
| SCHEMBL5123747 | 0.89 | AR (0.57) | ARNR3C1PGR | |
| SCHEMBL5123735 | 0.89 | AR (0.57) | ARNR3C1PGR | |
| SCHEMBL5115464 | 0.88 | AR (0.48) | ARNR3C1PGR | |
| SCHEMBL5122425 | 0.88 | AR (0.48) | ARNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | HIGUCHI ROBERT I | 2008-12-04 | — | — | US | disclosed |
| US-7214690-B2 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2007-03-29 | — | — | US | disclosed |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885NR3C1 57/4885PGR 92/4885 |
| US-20080300241-A9 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885NR3C1 60/4885PGR 97/4885 |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | AR 1/4885NR3C1 60/4885PGR 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.